Hims & Hers extended its rally for the second day on Friday, adding 6.76 percent to close at $49.41 apiece after its chief ...

The market for weight management medicines has been the hottest therapeutic area in the past two years. The pharmaceutical giant has far too much going its way. Analysts predict that the weight ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued its partnership with Hims & Hers concerning selling its weight-loss drug, ...

More than 20 million people globally are injecting themselves with GLP-1s... Weight-loss pills will only see that explode ...

Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide — are now available in the Indian market. Here’s how they work, how ...

There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...

These six stocks span numerous sectors, providing investors with opportunities in both growth and dividend yield.

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the 10 Stocks Delivering Eye-Popping Gains. Hims & Hers rebounded by 11.76 ...

Novo Nordisk is expanding access to its drug Wegovy through a new partnership with WeightWatchers, days after cutting ties with telehealth firm Hims & Hers. Starting July 1, WeightWatchers will ...